Nurix Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Nurix Therapeutics, Inc. | NRIX - NASDAQ |
$17.00-$18.00 | $19.00 | $18.06 | 11 million | 7/24/2020 |
| JP Morgan, Piper Sandler, Stifel | ||||||
Co-Manager(s): Needham & Company | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-07-02 Terms Added 2020-07-20 Terms Changed 2020-07-23 | ||||||
Nurix Therapeutics, Inc. Quote & Chart - Click for current quote - NRIX
IPO Boutique aggregates information on public companies and private companies, such as "NRIX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Nurix Therapeutics, Inc. (adapted from Nurix Therapeutics, Inc. prospectus):
They are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "NRIX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.